<DOC>
	<DOC>NCT00528879</DOC>
	<brief_summary>The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Key Inclusion Criteria Males and females, 18 to 77 years old, with type 2 diabetes and inadequate glycemic control Participants who have been receiving metformin at a total daily dose ≥1500 mg per day for at least 8 weeks Cpeptide ≥1.0 ng/mL Body mass index ≤45.0 kg/m^2 Serum creatinine level &lt;1.50 mg/dL for men or &lt;1.40 mg/dL for women. Key Exclusion Criteria Aspartate aminotransferase and/or alanine aminotransferase level &gt;3.0 times the upper limit of normal Serum total bilirubin level &gt;2 mg/dL Creatinine kinase level &gt;3 times upper limit of normal Symptoms of severely uncontrolled diabetes Serum creatinine level ≥1.50 mg/dL for men or ≥1.40 mg/dL for women Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetes Mellitus, Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Metformin</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
</DOC>